Effect of Sitagliptin on Postprandial Lipoprotein Metabolism

This study is not yet open for participant recruitment.

Verified by Ludwig-Maximilians - University of Munich, July 2009

First Received: July 14, 2009 No Changes Posted

Sponsor:	Ludwig-Maximilians - University of Munich
Information provided by:	Ludwig-Maximilians - University of Munich
ClinicalTrials.gov Identifier:	NCT00939939

Purpose

The goal of the study is to evaluate whether sitagliptin can affect postprandial lipoprotein metabolism in type 2 diabetic patients.

Condition	Intervention	Phase
Diabetes Mellitus Type 2	Drug: sitagliptin Drug: glimepiride	Phase IV

Study Type:

Interventional

Resource links provided by NLM:

MedlinePlus related topics: Diabetes

Drug Information available for: Glimepiride Sitagliptin Sitagliptin phosphate

U.S. FDA Resources

Further study details as provided by Ludwig-Maximilians - University of Munich:

Primary Outcome Measures:

AUC following standardized fat meal [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

other lipid parameters [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]

Arms	Assigned Interventions
sitagliptin: Experimental	Drug: sitagliptin
glimepirid: Active Comparator	Drug: glimepiride

Eligibility

Ages Eligible for Study:	19 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

type 2 diabetes
dietary therapy

Exclusion Criteria:

lipid-lowering therapy
anti-hyperglycemic drug therapy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00939939

Contacts

Contact: Klaus G Parhofer, MD

+49-89-7095 ext 3010

klaus.parhofer@med.uni-muenchen.de

Locations

Germany
Medical Dept. 2, Grosshadern, University Munich
Munich, Germany, 81377

Sponsors and Collaborators

Ludwig-Maximilians - University of Munich

More Information

No publications provided

Study ID Numbers:	KP MSD 01-08
Study First Received:	July 14, 2009
Last Updated:	July 14, 2009
ClinicalTrials.gov Identifier:	NCT00939939 History of Changes
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:

Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs
Diabetes Mellitus
Endocrine System Diseases
Enzyme Inhibitors
Cardiovascular Agents
Immunosuppressive Agents
Pharmacologic Actions

Protease Inhibitors
Sitagliptin
Dipeptidyl-Peptidase IV Inhibitors
Glimepiride
Hypoglycemic Agents
Therapeutic Uses
Diabetes Mellitus, Type 2
Anti-Arrhythmia Agents
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on February 08, 2010